Evidence map›Paper›PMID 42014802›Full record

ArticleScientific reports2026

CNDP1 (CTG)

Steffen A Hettler, Angela Moissl, Graciela E Delgado, Heyko Skladny, Winfried März, Bernhard K Krämer, Benito A Yard, Marcus E Kleber

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Steffen A HettlerVth Department of Medicine (Nephrology, Hypertensiology, Rheumatology, Endocrinology, Pneumology), Medical Faculty Mannheim, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany.ORCID http://orcid.org/0000-0002-8454-5221
Angela MoisslVth Department of Medicine (Nephrology, Hypertensiology, Rheumatology, Endocrinology, Pneumology), Medical Faculty Mannheim, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany.ORCID http://orcid.org/0000-0003-0302-2136
Graciela E DelgadoVth Department of Medicine (Nephrology, Hypertensiology, Rheumatology, Endocrinology, Pneumology), Medical Faculty Mannheim, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany.ORCID http://orcid.org/0000-0002-1272-7210
Heyko SkladnySynlab MVZ Humangenetik Mannheim, Mannheim, Germany.
Winfried MärzVth Department of Medicine (Nephrology, Hypertensiology, Rheumatology, Endocrinology, Pneumology), Medical Faculty Mannheim, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany.ORCID http://orcid.org/0000-0001-6083-8946
Bernhard K KrämerVth Department of Medicine (Nephrology, Hypertensiology, Rheumatology, Endocrinology, Pneumology), Medical Faculty Mannheim, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany.ORCID http://orcid.org/0000-0002-1718-2918
Benito A YardVth Department of Medicine (Nephrology, Hypertensiology, Rheumatology, Endocrinology, Pneumology), Medical Faculty Mannheim, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany. benito.yard@medma.uni-heidelberg.de.ORCID http://orcid.org/0000-0003-3451-3122
Marcus E KleberVth Department of Medicine (Nephrology, Hypertensiology, Rheumatology, Endocrinology, Pneumology), Medical Faculty Mannheim, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany.ORCID http://orcid.org/0000-0003-0663-7275

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Homozygous carriers of the CNDP1 (CTG)5 allele with diabetes mellitus are believed to have a lower risk of developing diabetic kidney disease compared to individuals carrying alleles with higher numbers of this CTG repeat. However, recent studies claimed that homozygosity for the (CTG)5 allele increases the risk of disease progression towards end-stage renal disease and even cardiovascular mortality, at least in women. Therefore, this study sought to confirm in a prospective manner in a cardiovascular high-risk cohort if individuals with two (CTG)5 alleles indeed have an increased cardiovascular mortality. 3,201 individuals from the LURIC study were included and followed for a median of 9.9 years. CNDP1 (CTG)n genotypes were assessed and related to all-cause and cardiovascular mortality. 1,157 (36.1%) patients carried the homozygous CNDP1 (CTG)5 genotype. No significant difference for all-cause and cardiovascular mortality was detected after multiple adjustments for cardiovascular risk factors, neither for the whole cohort nor for men or women, respectively. In this prospective cardiovascular high-risk cohort, homozygosity for the CNDP1 (CTG)5 allele was not associated with increased cardiovascular mortality compared to all other genotypes together. These findings do not confirm previous reports suggesting a sex-specific increase in cardiovascular mortality among women carrying two (CTG)5 alleles.

Indexed as

AllelesCardiovascular DiseasesDipeptidasesAgedFemaleGenetic Predisposition to DiseaseGenotypeHomozygoteHumansMaleMiddle AgedProspective StudiesRisk FactorsCNDP1 protein, humanDipeptidasesCardiovascular mortalityCarnosineCNDP1Diabetes mellitusDiabetic kidney diseaseLURIC

Identifiers

PMID42014802
PMCPMC13100134

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.